Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Comparing Hypertension Guidelines in CV Events

JAMA Cardiol; ePub 2018 May 23; Bundy, et al

Compared with the 2014 American College of Cardiology/American Heart Association (ACC/AHA) hypertension guideline, the 2017 hypertension guideline may increase the proportion of adults recommended for antihypertensive treatment and further reduce cardiovascular diseases and all-cause mortality in patients meeting treatment goals. This according to an analysis of data from the National Health and Nutrition Examination Survey 2013 to 2016 in which researchers estimated the proportions of US adults with hypertension or recommended for antihypertensive treatment according to the 2017 and 2014 hypertension guidelines. They determined:

  • According to the 2017 hypertension guideline, the prevalence of hypertension was 45.4% which was significantly higher than estimates per the 2014 hypertension guideline.
  • The proportion of individuals recommended for antihypertensive treatment was also significantly higher according to the 2017 guideline vs the 2014 guidelines.
  • Achieving the 2017 guideline treatment goals may further reduce 340,000 cardiovascular events and 156,000 total deaths annually compared with the 2014 guideline treatment goals.


Bundy JD, Mills KT, Chen J, Li C, Greenland P, He J. Estimating the association of the 2017 and 2014 hypertension guidelines with cardiovascular events and deaths in US adults. An analysis of national data. [Published online ahead of print May 23, 2018]. JAMA Cardiol. doi:10.1001/jamacardio.2018.1240.